ArticleThe pharmacogenomics journal2020
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
T Magnes et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.